CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth

被引：24
作者：
Mendelsohn, John [1 ]
Prewett, Marie [2 ]
Rockwell, Patricia [3 ]
Goldstein, Neil I. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] CUNY Hunter Coll, New York, NY 10021 USA
[4] Helio Genet, E Hanover, NJ USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 02期
关键词：
RECEPTOR MONOCLONAL-ANTIBODY; METASTATIC COLORECTAL-CANCER; SQUAMOUS-CELL CARCINOMA; PHASE-I; CETUXIMAB; COMBINATION; RESISTANCE; NECK; HEAD;
D O I：
10.1158/1078-0432.CCR-14-2491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human: murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.
引用
收藏
页码：227 / 229
页数：3
相关论文
共 13 条
  • [1] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578
  • [2] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
  • [3] PHASE-I AND IMAGING TRIAL OF INDIUM-111-LABELED ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY 225 IN PATIENTS WITH SQUAMOUS-CELL LUNG-CARCINOMA
    DIVGI, CR
    WELT, S
    KRIS, M
    REAL, FX
    YEH, SDJ
    GRALLA, R
    MERCHANT, B
    SCHWEIGHART, S
    UNGER, M
    LARSON, SM
    MENDELSOHN, J
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (02) : 97 - 104
  • [4] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Engelman, Jeffrey A.
    Zejnullahu, Kreshnik
    Mitsudomi, Tetsuya
    Song, Youngchul
    Hyland, Courtney
    Park, Joon Oh
    Lindeman, Neal
    Gale, Christopher-Michael
    Zhao, Xiaojun
    Christensen, James
    Kosaka, Takayuki
    Holmes, Alison J.
    Rogers, Andrew M.
    Cappuzzo, Federico
    Mok, Tony
    Lee, Charles
    Johnson, Bruce E.
    Cantley, Lewis C.
    Janne, Pasi A.
    [J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043
  • [5] GILL GN, 1984, J BIOL CHEM, V259, P7755
  • [6] Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
  • [7] The hallmarks of cancer
    Hanahan, D
    Weinberg, RA
    [J]. CELL, 2000, 100 (01) : 57 - 70
  • [8] Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
    Jiang, Ning
    Wang, Dongsheng
    Hu, Zhongliang
    Shin, Hyung Ju C.
    Qian, Guoqing
    Rahman, Mohammad Aminur
    Zhang, Hongzheng
    Amin, A. R. M. Ruhul
    Nannapaneni, Sreenivas
    Wang, Xiaojing
    Chen, Zhengjia
    Garcia, Gabriela
    MacBeath, Gavin
    Shin, Dong M.
    Khuri, Fadlo R.
    Ma, Jun
    Chen, Zhuo G.
    Saba, Nabil F.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (07) : 1826 - 1836
  • [9] GROWTH-STIMULATION OF A431 CELLS BY EPIDERMAL GROWTH-FACTOR - IDENTIFICATION OF HIGH-AFFINITY RECEPTORS FOR EPIDERMAL GROWTH-FACTOR BY AN ANTI-RECEPTOR MONOCLONAL-ANTIBODY
    KAWAMOTO, T
    SATO, JD
    LE, A
    POLIKOFF, J
    SATO, GH
    MENDELSOHN, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (05): : 1337 - 1341
  • [10] MASUI H, 1984, CANCER RES, V44, P1002
12